RECRUITING

MRI Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

Doctors leading this study hope to learn about a software that researchers at the University of Chicago have developed to help analyze radiographic images (different techniques for taking images that allow doctors to visualize the body's internal structures) of the prostate. Participation in this research will last about 12 months. There is a one-time MRI and 1-2 biopsies and then the investigator would like to follow the participant's progress.

Official Title

Magnetic Resonance Imaging (MRI) Derived Quantitative Risk Maps for Prostate Cancer Diagnosis Using Targeted Biopsy

Quick Facts

Study Start:2023-04-26
Study Completion:2026-05-01
Study Type:Not specified
Phase:Not Applicable
Enrollment:Not specified
Status:RECRUITING

Study ID

NCT05710380

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years
Sexes Eligible for Study:MALE
Accepts Healthy Volunteers:No
Standard Ages:ADULT, OLDER_ADULT
Inclusion CriteriaExclusion Criteria
  1. * Patients with known or suspected prostate cancer who have been referred for a diagnostic magnetic resonance imaging (MRI) exam of the prostate, to be followed by an MRI-guided fusion biopsy of the prostate.
  2. * Voluntary written informed consent before the MRI examination.
  1. * Subjects incapable of giving informed written consent.
  2. * Subjects who cannot adhere to the experimental protocols for any reason, or have an inability to communicate with the researcher;
  3. * Subjects with psychiatric disorders that affect their ability to consent for themselves will be excluded and not the entire population of patients with psychiatric disorders.
  4. * Prisoners.
  5. * Minor children (under the age of 18 years old).
  6. * Patients with previous treatments (surgery, radiation, focal ablation, hormone or other chemotherapy) for prostate cancer.

Contacts and Locations

Study Contact

Aytekin Oto, MD
CONTACT
773-702-8553
aoto@radiology.bsd.uchicago.edu

Principal Investigator

Aytekin Oto, MD
STUDY_CHAIR
University of Chicago Medicine Comprehensive Cancer Center

Study Locations (Sites)

University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois, 60637
United States

Collaborators and Investigators

Sponsor: University of Chicago

  • Aytekin Oto, MD, STUDY_CHAIR, University of Chicago Medicine Comprehensive Cancer Center

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-04-26
Study Completion Date2026-05-01

Study Record Updates

Study Start Date2023-04-26
Study Completion Date2026-05-01

Terms related to this study

Keywords Provided by Researchers

  • prostate cancer

Additional Relevant MeSH Terms

  • Prostate Cancer
  • Prostate Adenocarcinoma
  • Prostate Neoplasm